UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Sells 12,375 Shares of Vericel Co. (NASDAQ:VCEL)

UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lessened its position in Vericel Co. (NASDAQ:VCEL) by 11.4% during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 96,371 shares of the biotechnology company’s stock after selling 12,375 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC’s holdings in Vericel were worth $4,072,000 at the end of the most recent reporting period.

Other large investors have also added to or reduced their stakes in the company. Geneva Capital Management LLC boosted its stake in shares of Vericel by 61.4% during the 3rd quarter. Geneva Capital Management LLC now owns 1,104,386 shares of the biotechnology company’s stock valued at $46,660,000 after purchasing an additional 420,078 shares in the last quarter. Congress Asset Management Co. boosted its stake in shares of Vericel by 37.4% during the 3rd quarter. Congress Asset Management Co. now owns 1,291,720 shares of the biotechnology company’s stock valued at $54,575,000 after purchasing an additional 351,550 shares in the last quarter. Federated Hermes Inc. boosted its stake in shares of Vericel by 34.9% during the 2nd quarter. Federated Hermes Inc. now owns 840,787 shares of the biotechnology company’s stock valued at $38,575,000 after purchasing an additional 217,437 shares in the last quarter. TimesSquare Capital Management LLC boosted its stake in shares of Vericel by 54.8% during the 3rd quarter. TimesSquare Capital Management LLC now owns 590,145 shares of the biotechnology company’s stock valued at $24,934,000 after purchasing an additional 209,009 shares in the last quarter. Finally, Victory Capital Management Inc. boosted its stake in shares of Vericel by 51.5% during the 2nd quarter. Victory Capital Management Inc. now owns 611,146 shares of the biotechnology company’s stock valued at $28,039,000 after purchasing an additional 207,714 shares in the last quarter.

Vericel Stock Performance

Shares of Vericel stock opened at $57.01 on Friday. The stock has a market capitalization of $2.81 billion, a PE ratio of 950.17 and a beta of 1.71. Vericel Co. has a 52-week low of $32.31 and a 52-week high of $61.49. The company has a 50-day simple moving average of $49.63 and a two-hundred day simple moving average of $47.81.

Vericel (NASDAQ:VCEL) last issued its earnings results on Thursday, November 7th. The biotechnology company reported ($0.02) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.03. The business had revenue of $57.91 million during the quarter, compared to analysts’ expectations of $55.32 million. Vericel had a net margin of 1.56% and a return on equity of 1.48%. As a group, equities research analysts forecast that Vericel Co. will post 0.13 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Dominick Colangelo sold 17,500 shares of the business’s stock in a transaction that occurred on Wednesday, October 16th. The shares were sold at an average price of $41.38, for a total transaction of $724,150.00. Following the completion of the transaction, the chief executive officer now directly owns 220,937 shares of the company’s stock, valued at $9,142,373.06. The trade was a 7.34 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Steven C. Gilman sold 5,833 shares of the business’s stock in a transaction that occurred on Wednesday, October 2nd. The shares were sold at an average price of $40.35, for a total transaction of $235,361.55. Following the transaction, the director now directly owns 11,000 shares of the company’s stock, valued at $443,850. The trade was a 34.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 44,266 shares of company stock valued at $2,090,636. Insiders own 5.20% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on VCEL shares. Stephens raised shares of Vericel to a “strong-buy” rating in a research note on Monday, December 2nd. StockNews.com cut shares of Vericel from a “hold” rating to a “sell” rating in a research report on Thursday. Canaccord Genuity Group reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Tuesday, November 19th. HC Wainwright reissued a “buy” rating and set a $60.00 price target on shares of Vericel in a research report on Friday, November 8th. Finally, TD Cowen lifted their price target on shares of Vericel from $55.00 to $60.00 and gave the company a “buy” rating in a research report on Tuesday, August 27th. One analyst has rated the stock with a sell rating, six have assigned a buy rating and one has given a strong buy rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $59.71.

Vericel Profile

Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in North America. The company markets autologous cell therapy products comprising MACI, an autologous cultured chondrocytes on porcine collagen membrane for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns; and NexoBrid, a biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns.